Pacira | PCRX - Cash And Equivalent


Pacira reported $300.48M in Cash and Equivalent for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 1.54B
Cash and Equivalent USD 300.48M
Cost of Sales USD 55.19M
Current Assets USD 745.61M
Current Liabilities USD 313.16M
Debt USD 580.49M
EBIT USD 10.23M
EBITDA USD 54.32M
Employees 790
EPS Earnings Per Share USD 0.74
Equity Capital and Reserves USD 757.77M
Gross Profit on Sales USD 125.91M
Interest Expense on Debt USD 3.82M
Interest Income USD 5.01M
Loan Capital USD 378.1M
Market Capitalization USD 1.22B
Net Income USD -4.85M
Operating Expenses USD 170.87M
Operating Profit USD 10.23M
Ordinary Share Capital USD 44.9M
PE Price to Earnings USD 23.09
Pre-Tax Profit USD -1.93M
Sales Revenues USD 181.1M
Selling and Administration Expenses USD 77.2M
Stock USD 148.16M
Trade Creditors USD 30.12M
Trade Debtors USD 114.37M

Cash And Equivalent Change Date
Astellas Pharma JPY 188.37B 8.51B Mar/2025
Bristol-Myers Squibb USD 12.6B 1.72B Jun/2025
Ironwood Pharmaceuticals USD 88.56M 348K Dec/2024
J&J USD 38.47B 32.35B Mar/2025
Ligand Pharmaceuticals USD 67.67M 189.22M Jun/2025
Novo Nordisk A/S 18.44B 5.78B Jun/2025
Pacira USD 300.48M 16.87M Jun/2025
Perrigo USD 454.2M 44.3M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
Supernus Pharmaceuticals USD 144.71M 28.86M Jun/2025
Teva Pharmaceutical Industries USD 2.16B 464M Jun/2025
Xeris Pharmaceuticals USD 59.28M 12.34M Jun/2025
Zoetis USD 1.44B 286M Jun/2025